Open company graph database — free web & API
Login

DNA Chip Research Institute

DNAチップ研究所DNA Chip Research Inc.Alias株式会社DNAチップ研究所Alias
Ticker
—
Listed market
TYO
Country
Japan
Employees (non-consolidated)
0
Related companies
2
§01

Basic information

BASIC
Head office
9th Floor, KDX Musashi-Kosugi Building, 3-1200 Shin-Maruko Higashi, Nakahara-ku, Kawasaki City, Kanagawa 211-0004, Japan
Chief executive
Yoshiharu Hashimoto
Capital
100,000,000
Employees (non-consolidated)
0 people
Employees (consolidated)
Start date
1999-04-01
End date
§02

Websites

1 DOMAINS
§03

Business

7
Products handledResearch contract businessDiagnostic businessGenetic testingContract servicesResearch and developmentGenetic testing services
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Mitsui Chemicals Group's SDC Technologies, Inc.
Group Parent Shareholder
株式会社ディエヌエイチップ研究所
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

40 EVENTS

Founded DNH Chip Research Institute in Hodogaya-ku, Yokohama City, Kanagawa Prefecture (capital: 22 million yen), and started DNA chip research. Began joint research with Hitachi Software Engineering, Ltd. (now Hitachi Ltd.).Sources

Founded DNH Chip Research Institute in 1999. Developed DNA chips that comprehensively detect gene expression, aiming to contribute to future diagnostics and drug discovery. Released various general-purpose chips starting with domestically produced yeast chips. Simultaneously promoted the development of analysis software and equipment, establishing a business based on product sales.Sources

Started selling the first domestically produced general-purpose DNA chip "Yeast chip ver.1.0".Sources

Relocated headquarters and consolidated research systems.Sources

Relocated and consolidated headquarters to Tsurumi-ku, Yokohama City, in the "Yokohama Science Frontier" district.Sources

Changed the company name to 'DNA Chip Research Institute Inc.'.Sources

Started selling "AceGene Human Oligo Chip 30K".Sources

Changed trade name to "DNA Chip Research Institute, Inc.".Sources

Split one common stock into two (additional stocks due to split: 6,300 common stocks). Started selling "AceGene Mouse Oligo Chip 30K".Sources

Listed on the Tokyo Stock Exchange Mothers Market.Sources

Started selling "AceGene 30K on One Chip Version".Sources

Split one common stock into two (additional stocks due to split: 13,600 common stocks).Sources

Developed a new amino acid reagent and signed a licensing agreement with Sigma-Aldrich Japan Ltd.Sources

Started selling "AceGene Premium Human".Sources

Issued the first unsecured convertible bond with stock acquisition rights.Sources

Formed a strategic alliance with U.S. Agilent Technologies Inc. in the DNA microarray business.Sources

The full conversion of the first unsecured convertible bond with stock acquisition rights into shares has been completed.Sources

Developed "ConPath Chip" and "ConPath Navigator" and started a new contract analysis business.Sources

Started selling genetic analysis teaching materials "Hybrid Teacher" for school education.Sources

"Probe Bank" received the Encouragement Award at the 24th Kanagawa Industrial Technology Development Award.Sources

Transferred genome analysis business from Hubbit Genomics Inc. Started clinical trials for efficacy diagnosis of rheumatoid antibody drugs using RNA check. Started a breast cancer prognosis prediction testing service using "MammaPrint".Sources

Certified for Privacy Mark.Sources

Takeda Rika Industry Co., Ltd. formed a strategic partnership with U.S. WaferGeneBiosystems, Inc. Started exclusive domestic sales and contract services for next-generation ultra-high-speed ultra-sensitive real-time PCR device ("SmartChip").Sources

Formed a business alliance with Riken Genesis Co., Ltd. for genetic analysis services.Sources

Product announcement and sales start of clinical research gene expression database "iCIS-crdb".Sources

Product announcement and sales start of rheumatoid arthritis interview system "iRIS" for clinical settings.Sources

Product announcement and sales start of DNA extraction kit for hard tissues (teeth and bones) "TBONE EX KIT".Sources

Split ordinary shares into 100 shares (additional shares due to split: 3,355,803 ordinary shares) and adopted a unit share system (unit share: 100 shares).Sources

Formed a strategic partnership with U.S. Agilent Technologies Inc. for next-generation sequencing analysis business.Sources

Changed stock listing market to Tokyo Stock Exchange Second Section.Sources

Entered a capital and business alliance with Enplas Corporation (increased capital to 1.402 billion yen).Sources

Relocated research facilities and offices to Minato Ward, Tokyo.Sources

Transitioned from a company with audit & supervisory board to a company with an audit committee.Sources

Dissolved the capital and business alliance contract with Enplas Corporation.Sources

Formed a business alliance with Gene Metrics LLC on lung cancer compact panel business.Sources

Established a medical laboratory in Kawasaki City, Kanagawa Prefecture.Sources

Entered into a capital and business alliance agreement with Mitsui Chemicals, Inc.Sources

Relocated the office to Kawasaki City, Kanagawa Prefecture.Sources

The tender offer by Mitsui Chemicals, Inc. for our shares was successful.Sources

Implemented a share consolidation through a tender offer. Transitioned from a company with an Audit and Supervisory Committee to a company with a Board of Auditors. Delisted from the Tokyo Stock Exchange Standard Market.Sources

§07

News

23 ARTICLES

DNA Chip Laboratory Publishes Nanopore Sequencing Analysis ServiceSources

DNA Chip Laboratory offers a human whole-genome analysis service using nanopore sequencing. It can simultaneously obtain sequence and methylation information, enabling multi-faceted evaluation of analyses that were previously performed separately with a single sequencing dataset. It can also be used for structural variant and complex region analysis, supporting data acquisition tailored to research objectives.

On-Demand Release of Lung Cancer Online SeminarSources

The on-demand distribution of the online seminar "New Developments in Lung Cancer Companion Diagnostics: Considering Optimal Gene Testing and Treatment Choices", held on October 13, 2026, has begun. The distribution period is until November 30, 2026, and registration is required for viewing.

Notice of Restoration Work Due to PHP Vulnerability ResponseSources

From around 10:00 PM on October 21, our website was temporarily unavailable due to emergency maintenance by our server provider. It has now been restored and is available as usual. We apologize for any inconvenience caused to users.

Publication of Collaborative Research Paper on Long-Read SequencingSources

The DNA Chip Research Institute published a collaborative research paper on long-read sequencing. The publication date is October 6, 2026.

Online Seminar: New Developments in Companion Diagnostics for Lung CancerSources

An online seminar will be held on October 13, 2026, to discuss genetic testing and treatment strategies for lung cancer. The session will be chaired by Dr. Hisao Kasahara, and two presentations are planned. The seminar is also expected to be made available on demand afterward.

Notice of Transfer of Tbone EX Kit BusinessSources

DNA Chip Research Inc. announced that it will transfer its Tbone EX Kit business to Bio Dynamics Laboratory Inc., a subsidiary of Funakoshi Co., Ltd., effective October 5, 2026. Order acceptance will end with shipments scheduled for September 2026. For orders or inquiries from October onward, please contact the new distributor, Funakoshi Co., Ltd., or the new business operator, Bio Dynamics Laboratory Inc.

Online Seminar on Lung Cancer Genetic TestingSources

The online seminar scheduled for August 20, 2026, will discuss the latest trends and treatment strategies in genetic testing for lung cancer. Experts will explain the importance of genetic diagnosis and treatment for driver gene-positive lung cancer. Pre-registration is required, and on-demand streaming will be available later.

Start of Drug Addition Test for Lung Cancer Compact PanelSources

The DNA Chip Institute has expanded the indications for the Lung Cancer Compact Panel to include HER2 (ERBB2) gene mutations and has started testing. From August 3, 2026, we are offering tests with added new drugs.

Lung Cancer Compact Panel Drug Addition Testing Scheduled to BeginSources

DNA Chip Research Institute Inc. plans to add targeted drugs to the Lung Cancer Compact Panel and start testing from August 3, 2026. The HER2 (ERBB2) gene mutation will also be included as a target, expanding the number of applicable drugs. This will enable diagnosis with a broader range of anti-cancer agents.

Introduction to Agendia's MammaPrint webinarSources

The webinar, scheduled for July 24, 2026, will review the latest data and insights from MammaPrint that help predict chemotherapy and inform treatment decisions for early-stage HR+/HER2- breast cancer patients.

§09

Sources & updates

SOURCES
↑